NASDAQ
11.51USD
-0.08 (-0.69%)
We have scored 11 news catalysts on SELLAS Life Sciences Group, Inc. (SLS) over the past 12 months. The biggest single-day move next to one of them came Mar 21, 2026, when SLS closed −8.5%: “SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat”. Coverage across the window leans positive (average ticker sentiment +0.65). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.1B
P/E
—
EPS
—
Beta
2.52
52W range
1.39-15.88
Day range
11.37–11.64
Open
11.50
Prev close
11.59
Volume
3.2M
Avg volume
8.5M
Dividend
0.00
IPO
2008-03-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about SELLAS Life Sciences Group, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SLS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
